Experimental drug shows promise for rare immune disorders

This early-phase study tested the safety of rituximab, a drug that targets faulty white blood cells, in 7 adults with rare immune diseases like pulmonary alveolar proteinosis and severe candidiasis. Participants received several doses over 6 months and were monitored for 18 months afterward. The goal was to see if rituximab could help control these hard-to-treat conditions.